MX344247B - Sensibilidad a inhibidores de la angiogenesis. - Google Patents

Sensibilidad a inhibidores de la angiogenesis.

Info

Publication number
MX344247B
MX344247B MX2012001464A MX2012001464A MX344247B MX 344247 B MX344247 B MX 344247B MX 2012001464 A MX2012001464 A MX 2012001464A MX 2012001464 A MX2012001464 A MX 2012001464A MX 344247 B MX344247 B MX 344247B
Authority
MX
Mexico
Prior art keywords
determining
vegfr
gene
joint connection
present
Prior art date
Application number
MX2012001464A
Other languages
English (en)
Other versions
MX2012001464A (es
Inventor
Dorothee Foernzler
Paul Delmar
Stefan Scherer
Diether Lambrechts
Peter Carmeliet
Original Assignee
F Hoffmann-La Roche Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann-La Roche Ag * filed Critical F Hoffmann-La Roche Ag *
Publication of MX2012001464A publication Critical patent/MX2012001464A/es
Publication of MX344247B publication Critical patent/MX344247B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para mejorar la supervivencia total en un paciente que padece de una enfermedad por neoplasia maligna metastásica o una enfermedad implicando angiogénesis fisiológica y patológica mediante el tratamiento con un inhibidor de la angiogénesis, como bevacizumab, determinando la presencia de uno o más alelos variantes del gen del receptor 1 del factor de crecimiento endotelial vascular (VEGFR-1). La presente invención se invención adicionalmente proporciona métodos para mejorar la superviviencia libre de progresión en un paciente que padece de una enfermedad por neoplasia maligna metastásica o una enfermedad implicando angiogénesis fisiológica y patológica mediante el tratamiento con un inhibidor de la angiogénesis, como bevacizumab, determinando la presencia de uno o más alelos variantes del gen VEGFR-1. La presente invención también proporciona métodos para evaluar la sensibilidad de un paciente a un inhibidor de la angiogénesis determinando la presencia de uno o más alelos variantes del gen VEGFR-1.
MX2012001464A 2009-08-04 2010-08-03 Sensibilidad a inhibidores de la angiogenesis. MX344247B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167184 2009-08-04
PCT/EP2010/004761 WO2011015348A2 (en) 2009-08-04 2010-08-03 Responsiveness to angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
MX2012001464A MX2012001464A (es) 2012-05-08
MX344247B true MX344247B (es) 2016-12-09

Family

ID=42797289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001464A MX344247B (es) 2009-08-04 2010-08-03 Sensibilidad a inhibidores de la angiogenesis.

Country Status (13)

Country Link
US (1) US20120195858A1 (es)
EP (3) EP2894231B1 (es)
JP (2) JP5886197B2 (es)
KR (1) KR20130079303A (es)
CN (1) CN102575288A (es)
AU (1) AU2016203889A1 (es)
BR (1) BRPI1015134A2 (es)
CA (1) CA2766523A1 (es)
ES (1) ES2536195T3 (es)
IL (1) IL216798A (es)
MX (1) MX344247B (es)
SG (1) SG178209A1 (es)
WO (1) WO2011015348A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526900A (ja) * 2011-08-31 2014-10-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 血管新生阻害剤に対する応答性
MX2014006186A (es) 2011-11-23 2014-07-14 Hoffmann La Roche Capacidad de respuesta a los inhibidores de la angiogenesis.
ES2775213T3 (es) * 2013-06-13 2020-07-24 Ariosa Diagnostics Inc Análisis estadístico para la determinación no invasiva de aneuploidías de los cromosomas sexuales
CN104195231B (zh) * 2014-07-24 2017-01-18 益善生物技术股份有限公司 贝伐单抗疗效相关基因表达检测液相芯片试剂盒
EP3380194B1 (en) 2015-11-24 2023-11-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004232D0 (en) * 2000-02-24 2000-04-12 Zeneca Ltd Diagnostic method
EP1730306A2 (en) * 2004-03-01 2006-12-13 University of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
US20060057626A1 (en) * 2004-09-03 2006-03-16 Nichol Geoffrey M Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1

Also Published As

Publication number Publication date
EP2894231A1 (en) 2015-07-15
MX2012001464A (es) 2012-05-08
AU2010281043B2 (en) 2016-03-10
IL216798A (en) 2016-05-31
EP2894231B1 (en) 2017-01-04
AU2010281043A1 (en) 2012-01-19
WO2011015348A2 (en) 2011-02-10
CN102575288A (zh) 2012-07-11
ES2536195T3 (es) 2015-05-21
US20120195858A1 (en) 2012-08-02
EP3153592A1 (en) 2017-04-12
EP2462242A2 (en) 2012-06-13
AU2016203889A1 (en) 2016-06-30
JP2013501015A (ja) 2013-01-10
BRPI1015134A2 (pt) 2016-04-19
WO2011015348A3 (en) 2011-03-31
CA2766523A1 (en) 2011-02-10
JP2016144449A (ja) 2016-08-12
IL216798A0 (en) 2012-02-29
SG178209A1 (en) 2012-03-29
EP2462242B1 (en) 2015-04-01
KR20130079303A (ko) 2013-07-10
JP5886197B2 (ja) 2016-03-16

Similar Documents

Publication Publication Date Title
MX344247B (es) Sensibilidad a inhibidores de la angiogenesis.
WO2011133922A3 (en) Ultrasound based method and apparatus for stone detection and to facilitate clearance thereof
WO2009102895A3 (en) Method to predict response to pharmacological chaperone treatment of diseases
Korneva et al. Maladaptive aortic remodeling in hypertension associates with dysfunctional smooth muscle contractility
WO2011128852A3 (en) Automatic stage design of hydraulic fracture treatments using fracture height and in-situ stress
NO20076423L (no) Hydrazidkonjugater som billeddannende midler
DK1628570T3 (da) Fremgangsmåde til bestemmelse af hæmodynamiske parametre
PL2057467T3 (pl) Sposób diagnozowania choroby z udziałem przeciwciała przeciwko receptorowi AT1
DK1933590T3 (da) Fremgangsmåde til höreapparattilpasning
WO2006028645A3 (en) Method for remodeling bone and related sutures
WO2009111789A3 (en) Method and apparatus using ultrasound for assessing intracardiac pressure
BR112014012732A2 (pt) método para determinar pelo menos um parâmetro que seja adequado como uma base para identificar gestações de alto risco e sistema para identificar gestações de alto risco
Wagenseil et al. Elastin-insufficient mice show normal cardiovascular remodeling in 2K1C hypertension despite higher baseline pressure and unique cardiovascular architecture
Simova et al. Reproducibility of arterial stiffness indices in different vascular territories and between different observers
de Sa Ferreira et al. Three-section transmission-line arterial model for noninvasive assessment of vascular remodeling in primary hypertension
Gurovich et al. Patients with refractory angina have increased aortic wave reflection and wasted left ventricular pressure energy
Kritharis et al. Time course of flow-induced adaptation of carotid artery biomechanical properties, structure and zero-stress state in the arteriovenous shunt
WO2008057966A3 (en) A panel of biomarkers for peripheral arterial disease
RU2008104303A (ru) Способ диагностики сосудистого ремоделирования при артериальной гипертонии
Drapkina Rosuvastatin significantly improves arterial stiffness parameters by pulse-wave analysis in high risk patients with arterial hypertension and dyslipidemia
MX2023011307A (es) Metodo de seleccion de paciente con hipertension arterial pulmonar y biomarcador.
Mannarino Atherosclerotic Renal Artery Stenosis: is there still a reason for renal revascularization?
UA75072U (ru) Способ оценки эффективности лечения эфонидипином больных ишемической болезнью сердца со стенокардией и артериальной гипертензией
Pietri et al. PP. 18.10: ASSOCIATION OF PROTHROMBOTIC INDICES WITH TARGET ORGAN DAMAGE IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME
Ratto et al. PP. 18.08: LEFT VENTRICULAR DILATATION AND EARLY SIGNS OF RENAL DAMAGE IN PRIMARY HYPERTENSION

Legal Events

Date Code Title Description
FG Grant or registration